Fear of pain (FOP) and its effect on placebo analgesia was investigated. It was hypothesized that FOP should interfere with placebo-mediated pain inhibition and result in weaker placebo responding in pain intensity, pain unpleasantness, stress, and event-related potentials to contact heat pain. Thirty-three subjects participated in a balanced 2 condition (natural history, placebo)×3 test (pretest, posttest 1, posttest 2) within-subject design, tested on 2 separate days. FOP was measured by the Fear of Pain Questionnaire and subjective stress by the Short Adjective Check List. Placebo effects were found on reported pain unpleasantness and N2 and P2 amplitudes. FOP was related to reduced placebo responding in pain unpleasantness, but this was only evident for the subjects who received the placebo condition on day 1. Subjects who received the placebo condition on day 1 experienced more pretest stress than those who received the placebo condition on day 2 (ie, reversed condition order), and this explained the interaction effect on placebo responding. FOP was related to reduced placebo responding on P2 amplitude, whereas placebo responding on N2 amplitude was unaffected by FOP. Higher placebo responses on N2 and P2 amplitudes were both related to higher placebo analgesic magnitude in pain unpleasantness. In conclusion, increased FOP was found to reduce subjective and electrophysiological placebo analgesic responses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pain.2011.07.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial.
Clin Exp Nephrol
January 2025
Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ, USA.
Background: Despite of long-lasting tolvaptan treatment, individual renal outcomes are unclear in autosomal dominant polycystic kidney disease (ADPKD). This post-hoc analysis of the TEMPO 3:4 trial aimed to evaluate the predictability of estimated height-adjusted total kidney volume growth rate (eHTKV-α) on renal outcomes.
Methods: In TEMPO 3:4, 1445 patients with ADPKD were randomised to tolvaptan or placebo for 3 years.
Glutamatergic Medications for Obsessive-Compulsive and Related Disorders: A Systematic Review and Meta-Analysis.
JAMA Netw Open
January 2025
Center for OCD and Related Disorders, Massachusetts General Hospital, Boston.
Importance: Obsessive-compulsive and related disorders (OCRDs) encompass various neuropsychiatric conditions that cause significant distress and impair daily functioning. Although standard treatments are often effective, approximately 60% of patients may not respond adequately, underscoring the need for novel therapeutic approaches.
Objective: To evaluate improvement in OCRD symptoms associated with glutamatergic medications as monotherapy or as augmentation to selective serotonin reuptake inhibitors, with a focus on double-blind, placebo-controlled randomized clinical trials (RCTs).
Z hypnotics in the management of narcolepsy: a case series.
J Clin Sleep Med
December 2024
Sleep Disorders & Research Center, Department of Sleep Medicine, Henry Ford Health System, Detroit, MI.
Study Objectives: Here we report our experience treating patients with narcolepsy using benzodiazepine receptor agonists (BzRA), zolpidem (Zol) or eszopiclone (Esz) taken at bedtime for both excessive daytime sleepiness (EDS) and cataplexy.
Methods: We reviewed the medical records of 53 patients diagnosed with narcolepsy, between 2002 and 2023. Twenty-three patients, 8 with type1 (NT1), 13 with type 2 (NT2) and 2 with secondary narcolepsy, were treated with BzRA's (20 Zol and 3 Esz).
Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review.
Autoimmun Rev
December 2024
Rheumatology Department, Guy's and St Thomas' NHS Trust, London, United Kingdom.
Introduction: The use of Janus kinase inhibitors (JAKis) in immune-mediated inflammatory diseases (IMIDs) beyond licence is expanding rapidly. The aim of this scoping review was to identify and present the available evidence on the efficacy of JAKis in all conditions without marketing authorisation.
Methods: Through a systematic literature search we identified studies including 5 or more patients that assessed the use of any JAKi for any efficacy outcome.
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.
Am J Psychiatry
January 2025
Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York (Pagni, Zeifman, Mennenga, Carrithers, Goldway, O'Donnell, Ross, Bogenschutz); School of Life Sciences, Arizona State University, Tempe (Mennenga); Department of Psychology, New York University, New York (Goldway); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Bhatt).
Article Synopsis
- The study explored how psilocybin-assisted therapy (PAT) impacts personality traits in people with alcohol use disorder (AUD), hypothesizing it would reduce trait impulsiveness and improve drinking behavior.
- Eighty-four AUD patients were divided into two groups (psilocybin vs. placebo) and assessed for changes in personality traits over time, finding significant personality shifts in the psilocybin group, including reduced neuroticism and increased openness.
- The results indicated that lower impulsiveness correlated with decreased alcohol consumption, particularly among those who drank at risk before treatment, pointing to potential benefits of PAT in addressing both personality and drinking behaviors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!